Big news from PROT, CTIC, and STJ
crwefinancelogo2
signup3m
PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company’s successful international approach to commercializing its proprietary and patent pending stem cell technologies.
Mr. Michael Cohen, Chairman and CEO of Proteonomix, noted:
1. In the past few months the Company has undertaken an intensive international effort to establish strategic joint ventures in several European and Mid-Eastern nations for our Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI). We may be able to finalize the terms and conditions on at least one agreement arising from this initiative in the short term.